Does aspirin use reduce cardiovascular risk in diabetes?
The use of aspirin for the primary prevention of cardiovascular events in patients with type 2 diabetes mellitus is controversial. According to the findings of a Japanese trial, aspirin does not reduce the risk of cardiovascular events in this group of patients, unless they are aged 65 years and above.
Colwell
John A
JA
Medical University of South Carolina, 96 Jonathan Lucas Street, Charleston, SC 29425, USA. colwelja@musc.edu
D001241:Aspirin / Q000008:administration & dosage / Q000627:therapeutic use*; D050197:Atherosclerosis / Q000150:complications* / Q000453:epidemiology / Q000209:etiology / Q000517:prevention & control*; D002318:Cardiovascular Diseases / Q000453:epidemiology / Q000209:etiology / Q000517:prevention & control*; D003924:Diabetes Mellitus, Type 2 / Q000150:complications* / Q000188:drug therapy*; D006801:Humans; D010975:Platelet Aggregation Inhibitors / Q000008:administration & dosage / Q000627:therapeutic use*
D010975:Platelet Aggregation Inhibitors; D001241:Aspirin